en
Scientific article
Open access
English

Ammonium tetrathiomolybdate following ischemia/reperfusion injury: Chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models

Published inPLOS Medicine, vol. 14, no. 7, e1002310
Publication date2017
Abstract

Early revascularization of ischemic organs is key to improving outcomes, yet consequent reperfusion injury may be harmful. Reperfusion injury is largely attributed to excess mitochondrial production of reactive oxygen species (ROS). Sulfide inhibits mitochondria and reduces ROS production. Ammonium tetrathiomolybdate (ATTM), a copper chelator, releases sulfide in a controlled and novel manner, and may offer potential therapeutic utility.

Keywords
  • Animals
  • Chelating Agents/pharmacology
  • Male
  • Molybdenum/pharmacology
  • Rats
  • Rats Wistar
  • Reperfusion Injury/drug therapy
Citation (ISO format)
DYSON, Alex et al. Ammonium tetrathiomolybdate following ischemia/reperfusion injury: Chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models. In: PLOS Medicine, 2017, vol. 14, n° 7, p. e1002310. doi: 10.1371/journal.pmed.1002310
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1549-1277
461views
186downloads

Technical informations

Creation09/20/2017 11:31:00 AM
First validation09/20/2017 11:31:00 AM
Update time03/15/2023 2:16:27 AM
Status update03/15/2023 2:16:26 AM
Last indexation03/17/2024 11:43:37 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack